http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 24 Feb 2026 06:37:11 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Armata+Pharmaceuticals+%28ARMP%29+PT+Lowered+to+%2415+at+H.C.+Wainwright/26046287.html <p>H.C. Wainwright analyst Joseph Pantginis lowered the price target on Armata Pharmaceuticals (NYSE: ARMP) to $15.00 (from $19.00) while maintaining a Buy rating.</p><p>The analyst comments "Our perspective on QIDP designation: QIDP designation makes AP-SA02 eligible for Fast Track designation and Priority Review, and provides an additional five years of U.S. market exclusivity upon approval. The company plans to submit a request for Fast Track designation. We view this as incremental regulatory support as Armata prepares to initiate its Phase 3 superiority study in 2H26.We reiterate our Buy rating and are increasing our price target to $15 from $9."</p> http://www.streetinsider.com/Analyst+PT+Change/Armata+Pharmaceuticals+%28ARMP%29+PT+Lowered+to+%2415+at+H.C.+Wainwright/26046287.html Tue, 24 Feb 2026 06:37:11 -0500 ARMP http://www.streetinsider.com/Analyst+Comments/Armata+Pharmaceuticals+%28ARMP%29+PT+Lowered+to+%2415+at+H.C.+Wainwright/26046287.html <p>H.C. Wainwright analyst Joseph Pantginis lowered the price target on Armata Pharmaceuticals (NYSE: ARMP) to $15.00 (from $19.00) while maintaining a Buy rating.</p><p>The analyst comments "Our perspective on QIDP designation: QIDP designation makes AP-SA02 eligible for Fast Track designation and Priority Review, and provides an additional five years of U.S. market exclusivity upon approval. The company plans to submit a request for Fast Track designation. We view this as incremental regulatory support as Armata prepares to initiate its Phase 3 superiority study in 2H26.We reiterate our Buy rating and are increasing our price target to $15 from $9."</p> http://www.streetinsider.com/Analyst+Comments/Armata+Pharmaceuticals+%28ARMP%29+PT+Lowered+to+%2415+at+H.C.+Wainwright/26046287.html Tue, 24 Feb 2026 06:37:11 -0500 ARMP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Feb+23/26039208.html si-local-file:///var/storage/secattach/20260223/26039208.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Feb+23/26039208.html Mon, 23 Feb 2026 07:11:00 -0500 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Feb+23/26039208.html si-local-file:///var/storage/secattach/20260223/26039208.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Feb+23/26039208.html Mon, 23 Feb 2026 07:11:00 -0500 ARMP O.00168871 http://www.streetinsider.com/Corporate+News/Armata+Pharmaceuticals+receives+FDA+QIDP+designation+for+AP-SA02/26039127.html <p>Armata Pharmaceuticals Inc. (NYSE American: ARMP) announced that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product designation to AP-SA02, the company's bacteriophage therapeutic candidate for treating complicated bacteremia caused by Staphylococcus aureus.</p><p>The QIDP designation applies to intravenous use of AP-SA02 as adjunct treatment for complicated bacteremia caused by both methicillin-sensitive and methicillin-resistant S. aureus strains. The designation makes the drug candidate eligible for five additional years of market exclusivity under the Hatch-Waxman Act and potential Fast Track status for expedited FDA review processes.</p><p>"The FDA's decision to grant QIDP designation to AP-SA02 underscores the urgent need for innovative http://www.streetinsider.com/Corporate+News/Armata+Pharmaceuticals+receives+FDA+QIDP+designation+for+AP-SA02/26039127.html Mon, 23 Feb 2026 07:01:16 -0500 ARMP http://www.streetinsider.com/FDA/Armata+Pharmaceuticals+receives+FDA+QIDP+designation+for+AP-SA02/26039127.html <p>Armata Pharmaceuticals Inc. (NYSE American: ARMP) announced that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product designation to AP-SA02, the company's bacteriophage therapeutic candidate for treating complicated bacteremia caused by Staphylococcus aureus.</p><p>The QIDP designation applies to intravenous use of AP-SA02 as adjunct treatment for complicated bacteremia caused by both methicillin-sensitive and methicillin-resistant S. aureus strains. The designation makes the drug candidate eligible for five additional years of market exclusivity under the Hatch-Waxman Act and potential Fast Track status for expedited FDA review processes.</p><p>"The FDA's decision to grant QIDP designation to AP-SA02 underscores the urgent need for innovative http://www.streetinsider.com/FDA/Armata+Pharmaceuticals+receives+FDA+QIDP+designation+for+AP-SA02/26039127.html Mon, 23 Feb 2026 07:01:16 -0500 ARMP http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html <div class="xn-content"> <p class="prntac"><i>Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus </i></p><p class="prntac"><i>QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") has granted AP-SA02, the Company's http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+FDA+Qualified+Infectious+Disease+Product+%28QIDP%29+Designation+for+AP-SA02/26039086.html Mon, 23 Feb 2026 07:00:00 -0500 A.06822034 A.09231922 A.38032151 A.40958841 A.50208593 A.50213784 ARMP O.00168871 O.00303771 O.00366519 O.08407916 O.20026344 O.36670513 O.51065074